- For ripping off Medicaid, EpiPen maker Mylan pays Feds $465 million http://arstechnica.com/science/2016/10/for-ripping-off-medicaid-epipen-maker-mylan-pays-feds-465-million/ 6 comments worldnews
Linking pages
- CVS just announced a super cheap generic alternative to EpiPen | Ars Technica http://arstechnica.com/science/2017/01/cvs-just-announced-a-super-cheap-generic-alternative-to-epipen/ 102 comments
- Lawsuit: Mylan’s epic EpiPen price hike wasn’t about greed—it’s worse | Ars Technica https://arstechnica.com/science/2017/04/lawsuit-mylans-epic-epipen-price-hike-wasnt-about-greed-its-worse/ 54 comments
- Amid outrage and tumbling stocks, Mylan’s chairman pocketed $97M | Ars Technica https://arstechnica.com/science/2017/05/amid-outrage-and-tumbling-stocks-mylans-chairman-pocketed-97m/ 0 comments
- AT&T could discontinue Galaxy Note 7 sales over continued explosion fears | Ars Technica http://arstechnica.com/gadgets/2016/10/att-could-discontinue-galaxy-note-7-sales-over-continued-explosion-fears/ 0 comments
Linked pages
- Feds go after Mylan for scamming Medicaid out of millions on EpiPen pricing | Ars Technica http://arstechnica.com/science/2016/09/feds-go-after-mylan-for-scamming-medicaid-out-of-millions-on-epipen-pricing/ 1459 comments
- Rage mounts against pharma corp. that jacked cost of life-saving EpiPen by 400% | Ars Technica http://arstechnica.com/science/2016/08/rage-mounts-against-pharma-corp-that-jacked-cost-of-life-saving-epipen-by-400/ 197 comments
- EpiPen maker CEO to seething lawmakers: We’re doing the world a favor | Ars Technica http://arstechnica.com/science/2016/09/epipen-maker-ceo-to-seething-lawmakers-were-doing-the-world-a-favor/ 6 comments
- AT&T could discontinue Galaxy Note 7 sales over continued explosion fears | Ars Technica http://arstechnica.com/gadgets/2016/10/att-could-discontinue-galaxy-note-7-sales-over-continued-explosion-fears/ 0 comments
Related searches:
Search whole site: site:arstechnica.com
Search title: For ripping off Medicaid, EpiPen maker Mylan pays Feds $465 million | Ars Technica
See how to search.